In the realm of groundbreaking cancer therapies, TransCode Therapeutics, Inc. (Nasdaq: RNAZ), is stepping into the limelight. This RNA oncology champion is on a mission to revolutionize cancer treatment with the power of RNA therapeutics. Today, they’ve unveiled their ambitious plan, and it’s nothing short of awe-inspiring.
An underwritten public offering that shakes the very foundations of possibility. TransCode Therapeutics is offering a staggering 15,700,000 shares of its common stock, and if that doesn’t blow your mind, they’re throwing in pre-funded warrants (“Pre-Funded Warrants”) for good measure. And the price? A mere $0.51 per share, a steal considering the boundless potential that lies within.
But here’s the kicker: each of these shares comes with a Pre-Funded Warrant, exercising at a minuscule $0.01. It’s a symbol of the Company’s commitment to democratizing access to groundbreaking cancer treatments.
This offering is not just about numbers; it’s a testament to TransCode Therapeutics’ dedication. The expected gross proceeds of approximately $8 million are just the beginning. And if that weren’t enough, there’s more to come. The underwriters have been granted a 45-day option to grab an additional 2,339,200 shares of common stock and/or Pre-Funded Warrants, all at the same public offering price – less the underwriting discount.
ThinkEquity, a visionary in its own right, stands as the sole book-running manager for this historic offering.
Mark your calendars; the closing act is expected around September 28, 2023, provided all customary conditions are met. The grand finale? TransCode Therapeutics intends to channel these net proceeds into a series of clinical trials for their lead therapeutic candidate, TTX-MC138. It’s a journey that promises to rewrite the story of cancer treatment, one step at a time, and it starts here.
In the realm of battling cancer, TransCode Therapeutics emerges as a beacon of hope. Their mantra? Cancer can be conquered, and RNA therapeutics are the key to unlocking a brighter future. This is not just a company; it’s a mission, a mission with the potential to rewrite the rules of cancer treatment.
Imagine a platform of drug candidates, each a potential game-changer, targeting a multitude of tumor types, all with one resounding goal: to transform patient outcomes. At the forefront stands TTX-MC138, a therapeutic candidate with a singular focus on the relentless enemy known as metastatic cancer. This adversary claims nearly 90% of all cancer-related lives, a staggering nine million souls each year, worldwide.
TransCode believes that TTX-MC138 holds the power to rewrite the narrative of cancer, from breast and pancreatic to ovarian and colon cancers, even glioblastomas. It’s a promise to dramatically alter clinical outcomes and bring renewed hope.
But there’s more to the story. Meet TTX-siPDL1, another warrior in the fight against tumors, targeting the formidable PD-L1. TransCode’s arsenal doesn’t stop there. They boast three cancer-agnostic programs, each more revolutionary than the last. TTX-RIGA, a visionary RNA-based agonist of the retinoic acid-inducible gene I, is designed to awaken an immune response within the tumor’s microenvironment.
TTX-CRISPR steps in with a CRISPR/Cas9-based therapy platform, poised to repair or eliminate cancer-causing genes within the very heart of tumor cells. Finally, there’s TTX-mRNA, an mRNA-based platform crafting cancer vaccines with the power to rally cytotoxic immune responses against the enemy—tumor cells.
TransCode Therapeutics isn’t just rewriting the script; it’s authoring a new chapter in the battle against cancer. They’re the storytellers of hope, the architects of change, and the champions of a future where cancer is not a conqueror but a conquered.